Skip to content
The Policy VaultThe Policy Vault

Repatha (evolocumab subcutaneous injection - Amgen) — Cigna

Heterozygous Familial Hypercholesterolemia

Initial criteria

  • Patient meets indication-specific Initial Therapy criteria as defined in policy (see related sections)
  • If patient has not previously received approval from the Coverage Review Department and is currently receiving or restarting Repatha, must meet Initial Therapy criteria

Reauthorization criteria

  • Patient is currently receiving Repatha
  • According to the prescriber, the patient has experienced a response to therapy